{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:12:50Z","timestamp":1784941970820,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012729","name":"Case Western Reserve University Clinical and Translational Science Collaborative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jcjo.2024.05.013","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T19:47:18Z","timestamp":1717271238000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular risk in anti-VEGF\u202ftreatment of neovascular age-related macular degeneration"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4247-2263","authenticated-orcid":false,"given":"David D.","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-4286","authenticated-orcid":false,"given":"Christopher M.","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Markle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-669X","authenticated-orcid":false,"given":"Jacqueline K.","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.05.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2012.10.003","article-title":"Diffusion of technologies for the care of older adults with exudative age-related macular degeneration","volume":"155","author":"Stein","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jcjo.2024.05.013_bib0002","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"2019","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0003","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/jcm11071834","article-title":"Comparative effectiveness of intravitreal anti-vascular endothelial growth factor therapies for managing neovascular age-related macular degeneration: a meta-analysis","volume":"11","author":"Matonti","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0004","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0005","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthal"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0006","unstructured":"CDC. Prevalence estimates | Vision and eye health surveillance system | CDC. Available at: https:\/\/www.cdc.gov\/visionhealth\/vehss\/estimates\/amd-prevalence.html. Accessed January 13, 2024."},{"key":"10.1016\/j.jcjo.2024.05.013_bib0007","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3390\/ijms23052592","article-title":"Exudative versus non-exudative age-related macular degeneration: physiopathology and treatment options","volume":"23","author":"Fernandes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0008","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"JMCP"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0009","first-page":"92","article-title":"Faricimab in the treatment landscape for retinal diseases: a review","volume":"16","author":"Wu","year":"2022","journal-title":"US Ophthalmic Rev"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0010","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3390\/jcm10112436","article-title":"New and innovative treatments for neovascular age-related macular degeneration (nAMD)","volume":"10","author":"Patel","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0011","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/eye.2013.233","article-title":"The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary","volume":"27","author":"Chakravarthy","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0012","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","article-title":"the effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration","volume":"132","author":"Sloan","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0013","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797108","article-title":"Efficacy and safety of anti-vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a mixed treatment comparison","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0015","doi-asserted-by":"crossref","unstructured":"Ngo Ntjam N, Thulliez M, Paintaud G, et al. Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs [e-pub ahead of print]. JAMA Ophthalmol. doi:10.1001\/jamaophthalmol.2021.0640, accessed XX, XX.","DOI":"10.1001\/jamaophthalmol.2021.0640"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaophthalmol.2019.4636","article-title":"Risk of death associated with intravitreal anti-vascular endothelial growth factor therapy: a systematic review and meta-analysis","volume":"138","author":"Reibaldi","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","article-title":"Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration","volume":"137","author":"Dalvin","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0018","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0019","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40264-014-0231-2","article-title":"Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis","volume":"37","author":"Pratt","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajo.2015.06.011","article-title":"Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism","volume":"160","author":"Schlenker","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0021","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaophthalmol.2018.0002","article-title":"Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti\u2013vascular endothelial growth factor medication use","volume":"136","author":"Thulliez","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.jcjo.2024.05.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jcjo.2024.05.013_bib0023","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0024","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0025","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0026","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/STROKEAHA.109.571000","article-title":"Neovascular age-related macular degeneration and the risk of stroke","volume":"41","author":"Hu","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0027","first-page":"219","article-title":"The relationship between age-related macular degeneration and cardiovascular disease: a meta-analysis","volume":"50","author":"Lee","year":"2021","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0028","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/IAE.0b013e31821dc66f","article-title":"Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study","volume":"31","author":"French","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0029","doi-asserted-by":"crossref","first-page":"e41325","DOI":"10.1371\/journal.pone.0041325","article-title":"Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0030","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ophtha.2016.06.053","article-title":"Introducing anti-vascular endothelial growth factor therapies for AMD did not raise risk of myocardial infarction, stroke, and death","volume":"123","author":"Yashkin","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12886-017-0586-0","article-title":"Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration","volume":"17","author":"Hanhart","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaophthalmol.2018.6150","article-title":"Association of age-related macular degeneration with risk of all-cause and specific-cause mortality in the National Health and Nutrition Examination Survey, 2005 to 2008","volume":"137","author":"Zhu","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0033","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/bjo.85.3.322","article-title":"Vision impairment predicts 5 year mortality","volume":"85","author":"McCarty","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0034","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0002-9394(03)00573-7","article-title":"Visual impairment and unintentional injury mortality: the national health interview survey 1986\u20131994","volume":"136","author":"Lee","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1167\/iovs.06-0283","article-title":"Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity","volume":"48","author":"Bandello","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2023.0610","article-title":"Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data","volume":"141","author":"Dorney","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.05.013_bib0037","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/lary.30395","article-title":"Prevalence of new-onset tinnitus after COVID-19 vaccination with comparison to other vaccinations","volume":"133","author":"Dorney","year":"2023","journal-title":"Laryngoscope"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T01:23:48Z","timestamp":1737681828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0008418224001534"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.05.013","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk in anti-VEGF\u202ftreatment of neovascular age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}